Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Pravat Mandal
Study ID
NCT07050173
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Repetitive Head Impacts

Eligibility Criteria

Sex
ALL
Age
30 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Gamma-glutamylcysteine (GGC) — DRUG
    400mg tablet orally (two times) per day.

Study Details

The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.

Key Dates

Start date
May 1, 2026
Status verified
Jun 2026
Primary completion
Nov 1, 2027
Completion
Dec 27, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Gamma - Glutamylcystiene
    Each participant will receive gamma-glutamyl cysteine (GGC) tablet orally 400mg (two times) per day once in the morning and once in the evening for 12 months.

Primary Outcome Measure

Changes in brain glutathione levels (mM) in people with Repetitive Head Injury (RHI) using Magnetic Resonance Spectroscopy in pre and post supplementation. [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UPMC Presbyterian HospitalPittsburghPennsylvania15213
Pravat K Mandal, PhD
[email protected]
412-699-9561
Nazia Pillar, Ms
[email protected]
8573702614
Pravat K Mandal, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Pittsburgh, PA

By research site
UPMC Presbyterian Hospital· Pittsburgh, PA

Related Studies